News
Hims & Hers, LifeMD stocks skyrocket after inking deal with Novo Nordisk to sell Wegovy
Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy. | Novo Nordisk and Hims & Hers struck a truce after sparring over compounded versions of the pharma giant's branded GLP-1 drugs.
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...
We recently published a list of These 10 Firms Soared Last Week, Here’s Why. In this article, we are going to take a look at ...
Hims & Hers Health (NYSE:HIMS) stock spikes, risking a short squeeze given its elevated short interest. Read more here.
Novo Nordisk is expanding access to its GLP-1 drug Wegovy via telehealth, partnering with Hims and Hers, Ro, and LifeMD.
Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...
Asianet Newsable on MSN3d
Where Is Hims & Hers Stock Headed After Wegovy Tie-Up? Retail Traders Bet On Rebound To Over 2-Month HighNeedham called the tie-up a “groundbreaking partnership” and said it alleviates investor concerns around Hims’ ability to hit ...
Novo Nordisk, the maker of Wegovy, announced exclusively on " Good Morning America " Tuesday that the medication will soon be available for purchase through the telehealth companies Ro, Hims and ...
Hims & Hers Health partners with Novo Nordisk (NVO) to offer Wegovy, boosting weight-loss solutions. See why I remain ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback